The dismissal of breach-of-contract claims removes the most direct liability theory, but the surviving unjust enrichment and Chapter 93A claims keep $14.3M in potential exposure alive. Monitor for summary judgment motions on the remaining claims and any settlement discussions, as the case now hinges on equitable rather than contractual theories.
COLL drugs
COLL drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 20 $27.54entry
- T+1 · 3mo ago −1.56%α −1.97% · $27.11
- T+5 · 3mo ago −3.99%α −5.11% · $26.44
- T+20 · 2mo ago −17.32%α −17.20% · $22.77
- T+60 · 4d ago −8.06%α −6.98% · $25.32
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Collegium Pharmaceutical won partial dismissal of Walgreens' breach-of-contract lawsuit in Massachusetts federal court. The court dismissed Walgreens' breach of contract and implied covenant claims (Counts I and II) with prejudice, finding no contractual relationship existed between the parties. However, Walgreens' unjust enrichment claim (Count IV) and Massachusetts Chapter 93A unfair/deceptive trade practices claim (Count III) survived the motion to dismiss, with Walgreens seeking $14.3 million in damages for allegedly delayed product returns. The case proceeds on these two claims, creating ongoing litigation risk but removing the most direct contractual liability exposure.
Court Ruling Details
Key Facts
- Court dismissed breach of contract (Count I) and implied covenant (Count II) claims against Collegium, finding no enforceable contract existed between Walgreens and Collegium.
- Walgreens' unjust enrichment claim (Count IV) survived, alleging Collegium retained $14,321,229.99 in value from products Walgreens could not return due to delayed Form 222 authorizations.
- Walgreens' Chapter 93A unfair/deceptive trade practices claim (Count III) survived the motion to dismiss.
- The case was originally filed in June 2025 in Illinois, dismissed for lack of personal jurisdiction in February 2026, and refiled in Massachusetts in March 2026.
- Collegium's statute of limitations defense was not resolved at this stage, with the court noting factual questions remain about when the alleged misconduct occurred.
Financial Impact
Walgreens seeks $14.3 million in damages for allegedly unreturned product value; Collegium faces ongoing litigation costs and potential liability on two surviving claims
Risk Factors
- $14.3 million in potential damages on surviving unjust enrichment and Chapter 93A claims
- Ongoing litigation costs and management distraction
- Chapter 93A claim carries potential for treble damages and attorneys' fees if Collegium loses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-f9fa049eaf-COLL |
Track record
24 reports on COLL
1 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +0.28% at T+1 after the Aug 13, 2026 report. 1 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $25.68 Now $25.43 −0.97% settles Nov 17
- Nov 10, 20266d ago SC 13G/A Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $24.47 to $24.81 Now $25.43 +3.92% ▲ +1.39% +0.07% vs SPY
- Nov 9, 20267d ago Institutional Cluster Bearish 4/10 Entry $24.47 to $24.81 Now $25.43 −3.92% ▼ −1.39% −0.07% vs SPY
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $25.16 to $24.21 Now $25.43 +1.07% ▼ −3.78% −4.09% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $23.80 to $23.68 Now $25.43 +6.85% ▼ −0.50% −0.03% vs SPY
- Oct 29, 202618d ago SC 13G/A Neutral 3/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 29, 202618d ago Press Release Neutral 2/10 Entry $24.03 to $23.80 Now $25.43 +5.83% ▼ −0.96% +0.82% vs SPY
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $23.50 to $22.96 Now $25.43 +8.21% ▼ −2.30% −1.78% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers